Key Highlights

  • 1.01 is the per-share loss projected for Helus Pharma in the screener snapshot, compared with losses of 2.5 at Tevogen, 0.13 at TuHURA and 0.21 at Milestone, while the snapshot lacks confirmed call times.
  • 686.12 million is the USD valuation of Helus Pharma in the snapshot, topping USD 100.56 million for Tevogen, USD 96.86 million for TuHURA and USD 82.44 million for Milestone.
  • 166.4 million is the USD cash Helus Pharma held on June 30, 2026, against USD 170.6 million at Milestone, USD 1.08 million at Tevogen and USD 1.0 million at TuHURA, a wide spread in funding capacity.
  • 47.8 million is the USD loss Helus Pharma booked in its first fiscal quarter, versus USD 28.6 million at Milestone, USD 5,761,940 at Tevogen and USD 8.7 million of combined operating costs at TuHURA, by calculation.

Helus Pharma (NASDAQ:HELP): Phase 3 Topline Data Expected in Fourth-Quarter 2026

Helus Pharma (NASDAQ:HELP), formerly Cybin, will publish second-quarter fiscal 2027 results ahead of the opening bell on November 13, 2026. The consensus EPS estimate is -1.01, and the screener snapshot lists a valuation of USD 686.12 million, the biggest of the four. The period spans a three-month window ended September 30, 2026, with the fiscal year closing on March 31. For the prior-year period ended September 30, 2025, the loss was USD 33.7 million. In the first fiscal quarter that ended June 30, 2026, the loss reached USD 47.8 million versus USD 24.6 million, which by calculation is about 1.9 times, operating costs were USD 37.5 million versus USD 23.9 million, and cash stood at USD 166.4 million after a USD 50 million offering in June 2026. Enrolment in the Phase 3 APPROACH study of major depressive disorder has finished, and topline data are due in fourth-quarter 2026. Helus Pharma (NASDAQ:HELP) set up an at-the-market program worth USD 100 million in December 2025, meaning dilution could follow, while its release offered neither numeric outlook nor a runway estimate. Phase 2 results cited include a MADRS drop of roughly 23 points at 12 months for HLP003, while HLP005 should Yield a development candidate in late 2027.

Tevogen Inc. (NASDAQ:TVGN): Deepest Loss Estimate at 2.5 and Thin Cash

Tevogen Inc. (NASDAQ:TVGN) will publish third quarter 2026 results once trading ends on November 13, 2026. The consensus EPS estimate is -2.5, and the screener snapshot lists a valuation of USD 100.56 million. That figure sits far above the book position, a stockholders' Deficit of USD 8,888,760 and the snapshot numbers look odd for a company holding USD 1.08 million in cash, so the numbers are flagged. Last quarter's loss was USD 1.52 a share, alongside operating expenses of USD 5,662,376 and a bottom-line loss of USD 5,761,940. Total liabilities were USD 13,616,501 compared with total Assets of USD 4,727,741, and USD 1,651,000 in notes payable were in default. Shares climbed from 4,255,107 on June 30 to 6,511,540 by August 10. Tevogen Inc. (NASDAQ:TVGN) finished a Phase 1 trial of TVGN 489 and will not start another clinical study until funding arrives, although management said cash, available loans and a grant ought to cover no less than 12 months. Cash was USD 1,082,155, equal to roughly a month's worth of operating cash burn over six months of USD 5,739,172, by calculation. A Loan from a related party stood at USD 6.4 million, up from USD 4.4 million, with USD 11.0 million still available; the six-month loss was USD 11,208,195.

TuHURA Biosciences, Inc. (NASDAQ:HURA): Estimate 0.13 and a Funding Gap

TuHURA Biosciences, Inc. (NASDAQ:HURA) will publish third quarter 2026 results ahead of the opening bell on November 13, 2026. The consensus EPS estimate is -0.13, and the screener snapshot lists a valuation of USD 96.86 million. Below USD 100 million, micro-cap and nano-cap names may prove volatile and thinly traded. Published coverage did not turn up a loss or per-share figure for last quarter, yet R&D climbed USD 1.7 million to USD 6.6 million and G&A edged up USD 0.3 million to USD 2.1 million, giving combined operating costs of USD 8.7 million by calculation. Taken together, the figures show how heavily the company leans on outside financing. Cash used in operations across six months was USD 13.0 million, versus cash of USD 1.0 million on June 30, 2026. TuHURA Biosciences, Inc. (NASDAQ:HURA) depends on a USD 50 million Facility carrying 12% interest, of which merely USD 5.7 million has arrived, and management anticipates orphan status for IFx-2.0 in Merkel cell carcinoma during the latter half of 2026 and completion of Phase 3 enrolment in the latter half of 2027. Sales through the at-the-market program brought in USD 0.3 million in April and USD 0.1 million in July, and facility principal falls due April 21, 2031.

Milestone Pharmaceuticals Inc. (NASDAQ:MIST): Launch Traction and Obligations

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) will publish third quarter 2026 results ahead of the opening bell on November 13, 2026. The consensus EPS estimate is -0.21, identical to last quarter's loss of USD 0.21 a share, and the screener snapshot lists a valuation of USD 82.44 million. Below USD 100 million, small companies may prove volatile and thinly traded. Last quarter SG&A climbed to USD 22.6 million from USD 8.9 million, the loss came to USD 28.6 million versus USD 13.0 million, and CARDAMYST product sales were USD 0.56 million following a mid-February 2026 launch. More than 800 prescribers had put patients on therapy, and commercially covered lives grew from roughly 25% to roughly 50%. Milestone Pharmaceuticals Inc. (NASDAQ:MIST) had USD 170.6 million in cash versus USD 106.0 million at the prior year-end, which by calculation tops its market worth by about USD 88.2 million, yet obligations tied to royalties and convertibles add up to USD 141.0 million by calculation. Management plans to enrol patients in ReVeRA-301 during late 2026 and anticipates an EMA decision in first-half 2027. It anticipates that cash will carry operations into late 2027, with 124,497,980 shares outstanding plus 16,412,925 pre-funded warrants. Taken together, the cash position looks strong against the Market Value but leaves obligations to cover.

Where Things Stand

For Canadian investors sizing up the group: Helus Pharma (NASDAQ:HELP) has a projected loss of 1.01 and awaits APPROACH topline data in fourth-quarter 2026. Tevogen Inc. (NASDAQ:TVGN) has a projected loss of 2.5 and cash of USD 1.08 million. TuHURA Biosciences, Inc. (NASDAQ:HURA) has a projected loss of 0.13 and a facility drawn by merely USD 5.7 million. Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has a projected loss of 0.21 and launch traction, backed by USD 0.56 million in product sales. Helus Pharma, TuHURA and Milestone publish ahead of the open, whereas Tevogen publishes once trading ends. Funding and schedule updates will count most. This piece is informational only.